No approved hantavirus vaccine exists as of September 2026, with all candidates remaining in preclinical or very early clinical stages. Multiple mRNA and protein-subunit platforms, including those from Moderna-Korea University, UTMB, and University of Saskatchewan’s VIDO, have shown protection in rodent or hamster models, but none have completed human efficacy trials or met regulatory thresholds for licensure. A small Phase I safety study of an MVA-based candidate is ongoing into late 2026 without reported efficacy data. Standard development timelines from preclinical testing to approval span multiple years, and recent outbreaks have prompted additional funding without compressing these schedules enough for 2026 availability. Only an unforeseen emergency-use authorization for a near-complete candidate could alter the outcome before year-end.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
5% szansa
$135,595 Wol.
$135,595 Wol.
Dec 31, 2026
5% szansa
$135,595 Wol.
$135,595 Wol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists as of September 2026, with all candidates remaining in preclinical or very early clinical stages. Multiple mRNA and protein-subunit platforms, including those from Moderna-Korea University, UTMB, and University of Saskatchewan’s VIDO, have shown protection in rodent or hamster models, but none have completed human efficacy trials or met regulatory thresholds for licensure. A small Phase I safety study of an MVA-based candidate is ongoing into late 2026 without reported efficacy data. Standard development timelines from preclinical testing to approval span multiple years, and recent outbreaks have prompted additional funding without compressing these schedules enough for 2026 availability. Only an unforeseen emergency-use authorization for a near-complete candidate could alter the outcome before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Rynek otwarty: May 4, 2026, 10:39 AM ET
Wolumen
$135,595Data zakończenia
Jan 1, 2027Rynek otwarty
May 4, 2026, 10:39 AM ETRozstrzygający
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No approved hantavirus vaccine exists as of September 2026, with all candidates remaining in preclinical or very early clinical stages. Multiple mRNA and protein-subunit platforms, including those from Moderna-Korea University, UTMB, and University of Saskatchewan’s VIDO, have shown protection in rodent or hamster models, but none have completed human efficacy trials or met regulatory thresholds for licensure. A small Phase I safety study of an MVA-based candidate is ongoing into late 2026 without reported efficacy data. Standard development timelines from preclinical testing to approval span multiple years, and recent outbreaks have prompted additional funding without compressing these schedules enough for 2026 availability. Only an unforeseen emergency-use authorization for a near-complete candidate could alter the outcome before year-end.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Wolumen
$135,595Data zakończenia
Jan 1, 2027Rynek otwarty
May 4, 2026, 10:39 AM ETRozstrzygający
0x65070BE91...No approved hantavirus vaccine exists as of September 2026, with all candidates remaining in preclinical or very early clinical stages. Multiple mRNA and protein-subunit platforms, including those from Moderna-Korea University, UTMB, and University of Saskatchewan’s VIDO, have shown protection in rodent or hamster models, but none have completed human efficacy trials or met regulatory thresholds for licensure. A small Phase I safety study of an MVA-based candidate is ongoing into late 2026 without reported efficacy data. Standard development timelines from preclinical testing to approval span multiple years, and recent outbreaks have prompted additional funding without compressing these schedules enough for 2026 availability. Only an unforeseen emergency-use authorization for a near-complete candidate could alter the outcome before year-end.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania